新型钙调神经磷酸酶抑制药伏环孢素临床研究进展
Research progress in clinical application of a novel calcineurin inhibitor:voclosporin
邓伟萍 1胡长平 1罗平2
作者信息
- 1. 中南大学湘雅药学院药理学系,长沙 410078
- 2. 中南大学湘雅医院药学部,长沙 410008
- 折叠
摘要
伏环孢素是一种口服新型钙调神经磷酸酶抑制药,是环孢素A的衍生物,主要用于治疗自身免疫性疾病,如银屑病、非感染性葡萄膜炎和器官移植后排斥反应.2021年1月,基于两个Ⅱ期和Ⅲ期临床试验的积极结果,FDA批准伏环孢素与标准治疗方案联合用于治疗成人活动性狼疮肾炎.目前,也有研究在探索伏环孢素用于新型冠状病毒感染的肾移植患者.本文对伏环孢素的作用机制、药动学和药效学、用法用量、联合用药和疾病中应用进行归纳总结,为其临床用药提供参考.
Abstract
Voclosporin,an analogue of cyclosporine A,is an oral novel calcineurin inhibitor for autoimmune diseases such as plaque psoriasis,non-infectious uveitis and prevention of renal transplant rejection.Based on positive results from two pivotal phase Ⅱ and Ⅲ clinical trials,voclosporin was aproved by FDA in January 2021 for adult patients with active lupus nephritis in combination with a standrand treatment regimen.Recently,voclosporin has been explored for kidney transplant recipients with corona virus disease 2019(COVID-19).This article summarized the mechanism of action,pharmacokinetics and pharmacodynamics,dosage,co-administration and in-disease application of voclosporin in clinical treatment.
关键词
伏环孢素/狼疮肾炎/钙调神经磷酸酶抑制药/新型冠状病毒感染Key words
voclosporin/lupus nephritis/calcineurin inhibitor/corona virus disease 2019引用本文复制引用
基金项目
国家自然科学基金(82173817)
国家自然科学基金(82241025)
长沙市自然科学基金(kq2208366)
出版年
2024
NETL
NSTL
万方数据